Condition: Breast Neoplasms Interventions: Procedure: PET-CT examination; Procedure: Peripheral blood detection Sponsor: Shengjing Hospital Not yet recruiting (Source: ClinicalTrials.gov)
4h
Condition: Ovarian Cancer Interventions: Drug: Ropivacaine; Drug: Saline Solution Sponsors: Karolinska Institutet; Karolinska University Hospital Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
4h
Conditions: Cancer; Cancer Cachexia; Inflammation Interventions: Other: Resistance Training; Other: WB-EMS; Other: High-intensity interval training (HIIT); Other: Combined HIIT and Resistance Training (Combi) Sponsor: University of Erlangen-Nürnberg Medical School Recruiting (Source: ClinicalTrials.gov)
4h
Conditions: Small Intestinal NET; Carcinoid Heart Disease Interventions: Drug: Telotristat Ethyl; Drug: Lanreotide Sponsors: European Organisation for Research and Treatment of Cancer - EORTC; Ipsen Not yet recruiting (Source: ClinicalTrials.gov)
4h
Conditions: Oral Cavity Cancer; Mouth Neoplasm; Precancerous Conditions Intervention: Drug: Sintilimab Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Not yet recruiting (Source: ClinicalTrials.gov)
4h
Condition: Parkinson Disease Intervention: Diagnostic Test: Blood Assayed for CTCs Sponsor: NYU Langone Health Not yet recruiting (Source: ClinicalTrials.gov)
4h
Condition: Head and Neck Cancer Intervention: Drug: TAK-981 Sponsors: Presage Biosciences; Takeda Not yet recruiting (Source: ClinicalTrials.gov)
4h
Condition: Gastric Cancer Interventions: Drug: Sintilimab; Drug: Oxaliplatin; Drug: Capecitabine Sponsor: First Affiliated Hospital of Zhejiang University Not yet recruiting (Source: ClinicalTrials.gov)
4h
Conditions: Child; Determinants of Health; Qualitative Research; Cancer Intervention: Sponsors: University Hospital, Clermont-Ferrand; Université d'Auvergne Recruiting (Source: ClinicalTrials.gov)
4h
Conditions: Gastric Adenocarcinoma; Cancer Metastatic; Chemotherapy Effect Interventions: Drug: Pressurized intraperitoneal aerosol chemotherapy (PIPAC); Drug: Standard chemotherapy Sponsor: Assistance Publique - Hôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
4h
Conditions: Multiple Myeloma; Relapsed Refractory Multiple Myeloma Interventions: Drug: Elotuzumab, pomalidomide, dexamethasone; Drug: Anti-LAG-3 Monoclonal Antibody BMS-986016, pomalidomide, dexamethasone; Drug: Anti-TIGIT Monoclonal Antibody BMS-986207, pomalidomide, dexamethasone Sponsors: Multiple Myeloma Research Consortium; Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit...
4h
Conditions: Breast Cancer; Quality of Life; Physical Activity Intervention: Behavioral: Exercise Intervention Sponsors: University of California, San Diego; Haus of Volta Not yet recruiting (Source: ClinicalTrials.gov)
4h
Condition: Gynaecological Cancers Interventions: Drug: AZD6738; Drug: Olaparib Sponsors: Institute of Cancer Research, United Kingdom; Cancer Research UK; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
4h
Conditions: Rectal Cancer; Colorectal Cancer; Colon Cancer; Colo-rectal Cancer; Sarcopenia; Sarcopenic Obesity; Advanced Cancer; Recurrent Rectal Cancer Intervention: Device: Microstim 2v2 Stimulator Sponsor: London North West Healthcare NHS Trust Recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
4h
Condition: Epithelial Ovarian Cancer Intervention: Drug: adjuvant chemotherapy Sponsors: Japanese Gynecologic Oncology Group; Korean Gynecologic Oncology Group Recruiting (Source: ClinicalTrials.gov)
4h
Condition: Esophageal Squamous Cell Carcinoma Intervention: Drug: Anlotinib Hydrochloride, Paclitaxel, cisplatin Sponsors: Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
19h
Condition: Non-squamous Non-small Cell Lung Cancer Interventions: Drug: endostar/PD-1 inhibitor; Drug: endostar Sponsor: Dong Wang Recruiting (Source: ClinicalTrials.gov)
19h
Conditions: Urothelial Carcinoma Recurrent; Advanced Urothelial Carcinoma Intervention: Drug: Vactosertib(TEW-7197)/ Durvalumab Sponsors: MedPacto, Inc.; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
19h
Condition: Mammoplasty Patient Interventions: Procedure: Angiography; Procedure: MRI-Based Angiogram; Other: Quality-of-Life Assessment Sponsors: Ohio State University Comprehensive Cancer Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
19h
Condition: Epithelial Ovarian Cancer Intervention: Drug: adjuvant chemotherapy Sponsors: Japanese Gynecologic Oncology Group; Korean Gynecologic Oncology Group Recruiting (Source: ClinicalTrials.gov)
19h
Conditions: Pain; Prostate Cancer; Rectal/Anal Interventions: Procedure: Trans rectal ultrasound guided prostate biopsy; Device: Trans rectal ultrasound; Device: Prostate biopsy; Device: Periprostatic nerve block Sponsor: Assaf-Harofeh Medical Center Completed (Source: ClinicalTrials.gov)
20h
Conditions: Breast Cancer; Solid Tumor Intervention: Drug: OBT076, a CD205-directed antibody-drug conjugate Sponsor: Oxford BioTherapeutics Ltd Recruiting (Source: ClinicalTrials.gov)
20h
Condition: Extensive Stage Small Cell Lung Cancer Interventions: Drug: HLX10; Drug: carboplatin and etoposide; Drug: placebo Sponsor: Shanghai Henlius Biotech Recruiting (Source: ClinicalTrials.gov)
20h
Condition: Non Small Cell Lung Cancer Intervention: Drug: Pyrotinib Sponsor: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
20h
Condition: Lung Cancer Interventions: Other: Bronchoscopy; Other: Research Procedures Sponsors: NYU Langone Health; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
20h
Conditions: Prostate Cancer Screening; Prostate Cancer Interventions: Procedure: Magnetic Resonance Imaging (MRI); Procedure: Prostate-specific antigen (PSA) test Sponsors: University College, London; Medical Research Council; Cancer Research UK; Imperial College London; King's College London Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales...
20h
Condition: Prostatic Adenocarcinoma Intervention: Sponsor: University Hospital, Brest Recruiting (Source: ClinicalTrials.gov)
20h
Conditions: Pancreas Cancer; Pancreas Cyst Intervention: Other: Lateral Flow Assay (LFA) Sponsor: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
20h
Conditions: Cancer-related Problem/Condition; Quality of Life; Stress, Emotional Intervention: Behavioral: My Guide Sponsor: Northwestern University Not yet recruiting (Source: ClinicalTrials.gov)
20h
Condition: Skin Cancer Interventions: Other: Prevention video advertisement; Other: Prevention images for advertisement; Other: No Advertisement Sponsors: Stanford University; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
20h
Conditions: Healthy Subject; Nulliparous Interventions: Dietary Supplement: Dietary Intervention; Procedure: Dual X-ray Absorptiometry Sponsors: Fred Hutchinson Cancer Research Center; Breast Cancer Research Foundation; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
20h
Conditions: Advanced Malignant Solid Neoplasm; Caregiver; Metastatic Malignant Solid Neoplasm; Nurse; Nurse Practitioner; Oncologist; Physician Assistant; Progressive Neoplastic Disease; Recurrent Malignant Solid Neoplasm Interventions: Other: Behavioral, Psychological or Informational Intervention; Other: Educational Intervention; Procedure: Medical Examination; Other: Quality-of-Life Assessment; Other: Survey Administration; Behavioral: Telephone-Based Intervention...
20h
Conditions: PD-1; Chemoradiotherapy; Gastroesophageal Junction Cancer Intervention: Drug: PD-1 Sponsor: Peking University Not yet recruiting (Source: ClinicalTrials.gov)
20h
Conditions: Abdominal Aortic Aneurysm; Surgery; Arterial Disease Intervention: Drug: ACT guided heparinization Sponsors: Westfriesgasthuis; ZonMw: The Netherlands Organisation for Health Research and Development; VU University Medical Center; AIDS Malignancy Consortium Not yet recruiting (Source: ClinicalTrials.gov)
20h
Conditions: Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJC C v8; Stage IIB Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8 Interventions: Drug: Cisplatin; Biological: Pembrolizumab; Drug: Pemetrexed; Drug: Pemetrexed Disodium; Procedure: Therapeutic Conventional Surgery Sponsors:...
20h
Condition: Peripheral T Cell Lymphoma Interventions: Drug: Bortezomib; Drug: Etoposide; Drug: Cyclophosphamide; Drug: Pharmorubicin; Drug: Prednisone Sponsor: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
20h
Conditions: Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer Interventions: Drug: Durvalumab; Procedure: Surgery; Radiation: Radiotherapy Sponsors: Alliance Foundation Trials, LLC.; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
20h
Conditions: Cervical Cancer; Uterine Cervical Neoplasm; Uterine Neoplasms; Genital Neoplasm; Genital Neoplasm, Female; Uterine Diseases; Genital Diseases, Female; Neoplasms by Site; Neoplasms; Uterine Cervical Disease Intervention: Other: Sending of screening summon. Sponsors: Karolinska Institutet; Region Skane Not yet recruiting (Source: ClinicalTrials.gov)
20h
Condition: Metastatic Breast Cancer Intervention: Drug: Nivolumab Sponsors: Seoul National University Hospital; Seoul National University Bundang Hospital; Korean Cancer Study Group (KCSG); Eisai Korea; Ono pharmaceutical Korea Recruiting (Source: ClinicalTrials.gov)
20h
Conditions: Gastric Cancer; Neoadjuvant Therapy Interventions: Radiation: SIB-IMRT; Drug: S-1; Drug: SOX; Procedure: Surgery Sponsors: Jing Jin, M.D.; Beijing Hope Run Recruiting (Source: ClinicalTrials.gov)
20h
Condition: Cancer Intervention: Other: Participation with enhanced patient perioperative information Sponsor: Linkoeping University Recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
20h
Conditions: BRAF NP_004324.2:p.V600M; BRAF V600E Mutation Present; Metastatic Thyroid Gland Carcinoma; Refractory Thyroid Gland Carcinoma; Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IVB Differentiated T hyroid Gland Carcinoma AJCC v8 Interventions: Drug: Binimetinib; Drug: Encorafenib; Biological: Nivolumab Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI) Not yet recruiting...
20h
Conditions: Prostate Cancer; Androgen Deprivation Therapy Intervention: Behavioral: Walking football training Sponsors: Associacao de Investigacao de Cuidados de Suporte em Oncologia; Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.; University of Beira Interior; Federação Portuguesa de Futebol; University Institute of Maia; Câmara Municipal de Gaia Recruiting (Source: ClinicalTrials.gov)
20h
Conditions: Gastric Cancer; Adenocarcinoma of the Esophagogastric Junction Interventions: Drug: Nivolumab; Drug: Ipilimumab; Drug: Relatlimab; Drug: Oxaliplatin; Drug: Docetaxel; Drug: 5-Fluorouracil; Drug: Folic acid Sponsors: Jan Ellermeier; GWT-TUD GmbH Not yet recruiting (Source: ClinicalTrials.gov)
20h
Condition: Colorectal Cancer Interventions: Drug: Chemotherapy; Procedure: Radiofrequency ablation (RFA); Drug: In situ immunotherapy Sponsor: Assistance Publique - Hôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
20h
Conditions: Metastatic Malignant Neoplasm in the Brain; Radiation Therapy Recipient Interventions: Behavioral: Hand Function Test; Procedure: Navigated Transcranial Magnetic Stimulation; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for...
20h
Conditions: Acute Myeloid Leukemia in Remission; FLT3 Gene Mutation; Hematologic and Lymphocytic Disorder; High Risk Acute Myeloid Leukemia; Minimal Residual Disease Persistence; Therapy-Related Acute Myeloid Leukemia Interventions: Drug: Azacitidine; Drug: Venetoclax Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
20h
Real-world Study for the Safety of Albumin-Bound Paclitaxel in Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer Intervention: Other: Observational study Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
20h
Condition: Breast Cancer Interventions: Drug: Ipatasertib; Drug: Placebo; Drug: Palbociclib; Drug: Fulvestrant Sponsor: Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
20h
Conditions: Metastatic Melanoma; Renal Cell Carcinoma; Colon Cancer With MSI-H or dMMR Interventions: Drug: CD24Fc; Drug: Ipilimumab; Drug: Nivolumab Sponsors: OncoImmune, Inc.; Huntsman Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
20h
Condition: Advanced Hepatobiliary and Malignant Tumors Intervention: Drug: albumin-bound paclitaxel + oxaliplatin Sponsor: Dong Wang Not yet recruiting (Source: ClinicalTrials.gov)
20h
Authors: Buka D, Dvořák J, Richter I, Škrobánek P, Buchler T, Melichar B Abstract There is a growing corpus of evidence indicating that anti-VEGF therapy may normalize the abnormal tumor vasculature with the potential to re-program the tumor immune microenvironment to a more immunosupportive profile. Tumor vessel normalization increases tumor perfusion, and, consequently, oxygen and nutrient supply, and thus can be assumed to improve the general response to anticancer immunotherapy. The...
2m
ConclusionThe iodine quantification parameters derived from enhanced DE-CT during the VP may be useful for distinguishing lung squamous cell carcinoma from adenocarcinoma. (Source: Academic Radiology)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
5h
Publication date: Available online 22 August 2019Source: The Journal of Molecular DiagnosticsAuthor(s): Sally E. Trabucco, Kyle Gowen, Sophia L. Maund, Eric Sanford, David A. Fabrizio, Michael J. Hall, Evgeny Yakirevich, Jeffrey P. Gregg, Phil J. Stephens, Garrett M. Frampton, Priti S. Hegde, Vincent A. Miller, Jeffrey S. Ross, Ryan J. Hartmaier, Shih-Min A. Huang, James X. SunMicrosatellite instability (MSI) is an important biomarker for predicting response to immune checkpoint inhibitor therapy,...
5h
Publication date: Available online 22 August 2019Source: The Journal of Molecular DiagnosticsAuthor(s): Solène M. Evrard, Estelle Taranchon Clermont, Isabelle Rouquette, Samuel Murray, Sebastian Dintner, Yun-Chung Nam-Apostolopoulos, Beatriz Bellosillo, Mar Varela Rodriguez, Ernest Nadal, Klaus Hermann Wiedorn, Linea Melchior, Emma Andrew, Mary Jones, Jennifer Ridgway, Christina Frykman, Linda Lind, Mitja Rot, Izidor Kern, Ernst Jan M. Speel, Guido M.J.M. RoemenBefore initiating treatment of advanced...
5h
Role of miR‑34 in gastric cancer: From bench to bedside (Review). Oncol Rep. 2019 Aug 16;: Authors: Xiong S, Hu M, Li C, Zhou X, Chen H Abstract Gastric cancer (GC) is a prevalent digestive system malignancy that is associated with a poor prognosis specifically for advanced‑stage patients. MicroRNAs (miRNAs) are small, non‑coding RNAs that have been reported to play roles as oncogenes or tumour suppressors in all types of cancer, including GC, by post‑transcriptionally regulating...
6h
Tannic acid synergistically enhances the anticancer efficacy of cisplatin on liver cancer cells through mitochondria‑mediated apoptosis. Oncol Rep. 2019 Aug 16;: Authors: Geng N, Zheng X, Wu M, Yang L, Li X, Chen J Abstract Cisplatin (cis‑dichlorodiamine platinum, CDDP) is a potent antitumor agent. However, its clinical application is limited by its side effects and the development of drug resistance. Tannic acid (TA) has previously been reported to suppress tumor growth...
6h
Clinical significance and prospective molecular mechanism of C‑C motif chemokine receptors in patients with early‑stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Oncol Rep. 2019 Aug 13;: Authors: Zhou X, Liao X, Wang X, Huang K, Yang C, Yu T, Liu J, Han C, Zhu G, Su H, Qin W, Han Q, Liu Z, Huang J, Gong Y, Ye X, Peng T Abstract The present study aimed to determine the clinical significance and potential molecular mechanisms of C‑C motif chemokine receptor...
6h
Efficient primary culture model of patient‑derived tumor cells from colorectal cancer using a Rho‑associated protein kinase inhibitor and feeder cells. Oncol Rep. 2019 Aug 20;: Authors: Hong HK, Pyo DH, Kim TW, Yun NH, Lee YS, Song SJ, Lee WY, Cho YB Abstract In vitro culture of patient‑derived tumor cells offers many advantages in the development of novel therapies for colorectal cancer. Although various culture systems have been developed, the long‑term expansion of patient‑derived...
6h
Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825. Oncol Rep. 2019 Aug 19;: Authors: Wang X, Tan Y, Huang Z, Huang N, Gao M, Zhou F, Hu J, Feng W Abstract Diffuse large B‑cell lymphoma (DLBCL), the most common type of non‑Hodgkin's lymphoma, is classified into germinal center and activated B cell (ABC) subtypes. The myeloid differentiation primary response gene 88 (MYD88) L265P mutation is the most prevalent...
6h
Authors: Zhang L, Tao X, Fu Q, Ge C, Li R, Li Z, Zhu Y, Tian H, Li Q, Liu M, Hu H, Zeng B, Lin Z, Li C, Luo R, Song X Abstract Despite the increasing number of available therapeutic methods, the prognosis of non‑small cell lung cancer (NSCLC) remains poor. Furthermore, side effects are an important limiting factor in the treatment of NSCLC. Therefore, developing an efficacious, safe, affordable and easily accessible chemotherapeutic agent is necessary for NSCLC treatment. As a natural chemical...
6h
Expression of LXR‑β, ABCA1 and ABCG1 in human triple‑negative breast cancer tissues. Oncol Rep. 2019 Aug 14;: Authors: Pan H, Zheng Y, Pan Q, Chen H, Chen F, Wu J, Di D Abstract Previous studies have reported that liver X receptor (LXR), ATP‑binding cassette sub‑family G number 1 (ABCG1) and ATP‑binding cassette transporter number 1 (ABCA1), which are associated with cholesterol metabolism, may be associated with the development and progression of breast cancer. The expression...
6h
EMX2 is epigenetically silenced and suppresses epithelial‑mesenchymal transition in human esophageal adenocarcinoma. Oncol Rep. 2019 Aug 20;: Authors: Wang L, Jin J, Zhou Y, Tian Z, He B, Huang Y, Ding F Abstract Esophageal adenocarcinoma (EAC) is an aggressive and challenging disease to treat, with an overall five‑year survival rate of <20%. Early malignant cell dissemination contributes to this poor prognosis. Epithelial‑mesenchymal transition (EMT) induces the invasion...
6h
miR‑378a‑3p inhibits cellular proliferation and migration in glioblastoma multiforme by targeting tetraspanin 17. Oncol Rep. 2019 Aug 20;: Authors: Guo XB, Zhang XC, Chen P, Ma LM, Shen ZQ Abstract Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor and patients with this disease tend to have poor clinical outcome. MicroRNAs (miRs) are important regulators of a number of key pathways implicated in tumor pathogenesis. Recently, the expression of miR‑378...
6h
Publication date: September 2019Source: Journal of the Academy of Nutrition and Dietetics, Volume 119, Issue 9Author(s): Jennifer Doley, Krista Clark, Shaynee RoperAbstractClinical nutrition management (CNM) encompasses the varied roles of registered dietitian nutritionists (RDNs) with administrative responsibilities for clinical nutrition services within an organization. Although RDNs in CNM are typically employed in acute care, they are also employed in settings where management of nutrition services...
6h
This study could help to conveniently design preclinical studies using physiologically relevant conditions in (breast) cell models.Graphical abstract (Source: Journal of Functional Foods)
6h
In conclusion, the present study has identified several key genes that are potentially druggable genes or therapeutics targets in OS. Functional annotations revealed that the dysregulation of the ECM may contribute to OS development and, therefore, provided new insights to improve our understanding of the mechanisms underlying OS. PMID: 31432118 [PubMed - as supplied by publisher] (Source: Molecular Medicine Reports)
7h
In conclusion, the findings suggested that upregulation of TP73‑AS1 promoted cervical cancer progression by promoting CCND2 via the suppression of miR‑607 expression. PMID: 31432138 [PubMed - as supplied by publisher] (Source: Molecular Medicine Reports)
7h
In conclusion, STC1 expression levels were increased in the present study, and it was revealed that STC1 regulated glioblastoma malignancy. This phenotype was observed in the SMAD2/3 and SMAD4 pathways. PMID: 31432189 [PubMed - as supplied by publisher] (Source: Molecular Medicine Reports)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
7h
RAD18 contributes to the migration and invasion of human cervical cancer cells via the interleukin‑1β pathway. Mol Med Rep. 2019 Aug 06;: Authors: Lou P, Zou S, Shang Z, He C, Gao A, Hou S, Zhou J Abstract The E3 ubiquitin ligase RAD18 has been identified as an oncoprotein that exhibits prometastatic properties in various types of cancer; however, the role of RAD18 in cervical cancer (CC) remains unclear. In the present study, it was revealed that increased expression of...
7h
In this study, gene expression profiles were downloaded from the Gene Expression Omnibus database and an integrated analysis with the aim of detecting hub long non‑coding RNAs (lncRNAs) and their regulated, differentially expressed genes (DEGs) during treatment with oxaliplatin (OxPt) or irinotecan was conducted. A total of seven differentially expressed lncRNAs were correlated with OxPt resistance and 21 were correlated with resistance to SN‑38, the active metabolite of irinotecan. Gene Ontology...
7h
SREBP2 is upregulated in esophageal squamous cell carcinoma and co‑operates with c‑Myc to regulate HMGCR expression. Mol Med Rep. 2019 Aug 09;: Authors: Zhong C, Fan L, Li Z, Yao F, Zhao H Abstract Dysregulations of the mevalonate pathway (MVA) have been previously identified. Our previous study demonstrated that 3‑hydroxy‑3‑methylglutaryl‑coenzyme A reductase (HMGCR), the rate‑limiting enzyme of the MVA pathway, was upregulated in esophageal squamous cell carcinoma (ESCC)...
7h
Authors: Moon D, Kim J, Yoon SP Abstract The microbiome has recently attracted research interest in a variety of subjects, including cancer. In the present study, it was determined that reinforced clostridium media (RCM) for microbiome culture, exerts antitumor effects on renal cell carcinoma cells when compared to the microbiome 'X'. The antitumor effects of RCM were investigated for all ingredients of RCM, and the results revealed that yeast extract could be a candidate for the ingredient...
7h
Authors: Jiang X, Wu M, Xu X, Zhang L, Huang Y, Xu Z, He K, Wang H, Wang H, Teng L Abstract Dysregulation of collagen type XII α1 chain (COL12A1) has been found in several cancer types and could be involved in tumor progression. However, its clinical significance in gastric cancer (GC) remains under exploration. Online databases (Gene Expression Omnibus and UALCAN), reverse transcription‑quantitative PCR and immunohistochemistry were utilized in the present study to evaluate the expression...
7h
Targeting heterotopic ossification by inhibiting activin receptor‑like kinase 2 function (Review). Mol Med Rep. 2019 Aug 06;: Authors: Shi F, Gao J, Zou J, Ying Y, Lin H Abstract Heterotopic ossification (HO) refers to the appearance of osteoblasts in soft tissues under pathological conditions, such as trauma or infection. HO arises in an unpredictable way without any recognizable initiation. Activin receptor‑like kinase‑2 (ALK2) is a type I cell surface receptor for bone...
7h
An 8‑gene signature predicts the prognosis of cervical cancer following radiotherapy. Mol Med Rep. 2019 Jul 29;: Authors: Xie F, Dong D, Du N, Guo L, Ni W, Yuan H, Zhang N, Jie J, Liu G, Tai G Abstract Gene expression and DNA methylation levels affect the outcomes of patients with cancer. The present study aimed to establish a multigene risk model for predicting the outcomes of patients with cervical cancer (CerC) treated with or without radiotherapy. RNA sequencing training...
7h
Upregulated microRNA‑671‑3p promotes tumor progression by suppressing forkhead box P2 expression in non‑small‑cell lung cancer. Mol Med Rep. 2019 Aug 06;: Authors: Li ZY, Zhang ZZ, Bi H, Zhang QD, Zhang SJ, Zhou L, Zhu XQ, Zhou J Abstract In the present study, the expression of microRNA (miR)‑671‑3p in non‑small‑cell lung cancer (NSCLC) was detected via reverse transcription‑quantitative polymerase chain reaction analysis, and its role in cell proliferation, apoptosis, migration...
7h
Upregulation of Myc promotes the evasion of NK cell‑mediated immunity through suppression of NKG2D ligands in K562 cells. Mol Med Rep. 2019 Aug 09;: Authors: Lee YS, Heo W, Son CH, Kang CD, Park YS, Bae J Abstract c‑Myc is a characteristic oncogene with dual functions in cell proliferation and apoptosis. Since the overexpression of the c‑Myc proto‑oncogene is a common event in the development and growth of various human types of cancer, the present study investigated whether...
7h
In conclusion, niacin upregulates ApoM expression by increasing LXRα expression in vivo and in vitro. PMID: 31432166 [PubMed - as supplied by publisher] (Source: Molecular Medicine Reports)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.
7h
Curcumin protects the pancreas from acute pancreatitis via the mitogen‑activated protein kinase signaling pathway. Mol Med Rep. 2019 Aug 01;: Authors: Wang Y, Bu C, Wu K, Wang R, Wang J Abstract Curcumin has been demonstrated to reduce markers of inflammation during acute pancreatitis (AP). However, the underlying mechanisms of the protective effects of curcumin are unknown. In the present study the effects of curcumin in an AP animal model and cell models was examined and...
7h
Afatinib, an EGFR inhibitor, decreases EMT and tumorigenesis of Huh‑7 cells by regulating the ERK‑VEGF/MMP9 signaling pathway. Mol Med Rep. 2019 Aug 06;: Authors: Chen Y, Chen X, Ding X, Wang Y Abstract Transcatheter arterial embolization (TAE) therapy has been used in the treatment of inoperable hepatocellular carcinoma (HCC). However, tumor recurrence and metastasis are common in patients after TAE, and these processes may be caused by circulating tumor cells (CTCs). Epithelial‑mesenchymal...
7h
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου